Background: Malaria is a major public health problem throughout human history, particularly in the tropical and subtropical countries. Primaquine, introduced in 1950, for preventing relapse and sterilizes infectious sexual plasmodia. Methods: A retrospective study was performed for 610 patients (250 were male and 360 were female), (all ages) to study the efficacy of Primaquine in the treatment of falciparum malaria after receiving this drug for five days. Results: Five hundred and ninety three patients (97.2 %) were completely recovered from malaria within 3 to 5 days after receiving Primaquine tablets. Conclusion: In our opinion Primaquine should become the first line as antimalarial drug soon later for uncomplicated malaria, because of its high efficiency against infections with Plasmodiumfalciparum and P.vivax active stages.

Aim: Pulmonary hypertension (PH) is a progressive pulmonary vascular disease characterized by pulmonary artery remodeling and vasoconstriction resulting in elevated pulmonary arterial pressure and consequent right heart failure. In this study, we aimed to present our single center clinical experience with these patients. Method: 331 patients who were followed up in our center with the diagnosis of pulmonary arterial hypertension between 2013-2021 were evaluated by retrospective analysis method. Results: The mean age of the patients was 54.6, mean sPAB value was 75.4 mmHg and the mean follow-up period of the patients was recorded as 44.9 months. It was determined that 68.9% of them were female. When the etiological diagnoses were evaluated in order of frequency; congenital heart disease, chronic thromboembolic pulmonary hypertension (CTEPH), idiopathic pulmonary arterial hypertension (IPAH), collagen tissue disease, disproportionate pulmonary hypertension (group 2, group 3) and rare cases (pulmonary veno-occlusive disease (PVOD), portal hypertension (PoHT)). When the survival analysis is evaluated, the risk of mortality increases 1.021 times as the age increases. Men have a 1,863 times higher risk of mortality than women. The mortality risk of those with a congenital diagnosis is 0.36 times less than those with a diagnosis of IPAH. Negative correlation was found between functional class of patients and mortality (p<0.005). The risk of mortality increases 1.016 times as the SPAB increases. Conclusion: “Pulmonary hypertension is a disease with high mortality and includes different disease groups”. The follow-up of these patients in PAH centers and the use of special medications affect mortality rates.